BOB体育

Skip to main content
(352) 294-5000

Torge Rempe, MD, PhD : Research

Neurologist

Additional languages:
Spanish,
German
Photo of Torge Rempe
(352) 294-5000 MyUFHealth

Research at a glance

Top areas of exploration

  • Autoantibodies , 6 publications
  • Myelin-Oligodendrocyte Glycoprotein , 4 publications
  • Immunologic Factors , 4 publications
  • Leukoencephalopathy, Progressive Multifocal , 4 publications

Research activity

25 publications

387 citations

Why is this important?

Active clinical trials

SANOFI 16035 PERSEUS

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical鈥�

Investigator
Torge Rempe
Status
Accepting Candidates
Ages
18 Years - 55 Years
Sexes
All
TREAT-MS

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early鈥�

Investigator
Torge Rempe
Status
Accepting Candidates
Ages
18 Years - 60 Years
Sexes
All

My publications

25 publications

2025

Increased Intracranial Pressure in Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease.

The neurologist

鈥�

2024

Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

Multiple sclerosis and related disorders

鈥�

2024

Multiple Sclerosis: Clinical Update and Clinically-Oriented Radiologic Reporting.

Magnetic resonance imaging clinics of North America

鈥�

2024

Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Magnetic resonance imaging clinics of North America

鈥�

2023

Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates.

Multiple sclerosis and related disorders

鈥�